biotech analyst roundup Biotech Analyst Roundup: Psychedelics, Gene Therapy, Immunology & Regulatory Outlook Wall Street analysts delivered a wave of updated biotechnology research covering psychedelic medicine, rare diseases, immunology, ophthalmology, and oncology. While several companies continue to earn bullish ratings based on strong clinical pipelines and cash runways, others face valuation concerns, regulatory uncertainty, or commercialization challenges. Here’s a detailed…